You have 9 free searches left this month | for more free features.

decitabine

Showing 1 - 25 of 220

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)

Recruiting
  • AML
  • MDS
  • Tuebingen, Baden-Wuerttemberg, Germany
    University Hospital
Nov 30, 2023

Poor Graft Function Trial (Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist)

Not yet recruiting
  • Poor Graft Function
  • Decitabine
  • +3 more
  • (no location specified)
Jun 8, 2023

Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)

Not yet recruiting
  • Myeloid Malignancy
  • Acute Myeloid Leukemia
  • Cleveland, Ohio
    University Hospitals Seidman Cancer, Case Comprehensive Cancer C
Nov 8, 2023

Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)

Not yet recruiting
  • Ovarian Cancer
  • Decitabine
  • +3 more
  • Maywood, Illinois
    Loyola University Medical Center
Aug 1, 2023

Acute Myeloid Leukemia, MDS Trial (Cladribine, Cytarabine, Decitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Mar 1, 2023

Healthy Trial in San Antonio (Decitabine, Tetrahydrouridine)

Recruiting
  • Healthy
  • San Antonio, Texas
    Worldwide Clinical Trails Early Phase Services
Apr 14, 2023

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,

Active, not recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Decitabine
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Recurrent Acute Myeloid Leukemia Trial in Nashville (Venetoclax, Decitabine, Cedazuridine)

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Mar 22, 2023

Poor Graft Function Trial (decitabine, umbilical cord blood, Granulocyte-colony stimulating factor)

Not yet recruiting
  • Poor Graft Function
  • decitabine
  • +4 more
  • (no location specified)
Dec 29, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Decitabine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Refractory Aplastic Anemia Trial in Tianjin (Decitabine)

Terminated
  • Refractory Aplastic Anemia
  • Decitabine
  • Tianjin, Tianjin, China
    Regenerative Medicine Center
Aug 25, 2022

MDS, AML Trial in Bronx (Venetoclax, Decitabine)

Recruiting
  • MDS
  • AML
  • Bronx, New York
    Montefiore Medical Center
Jul 22, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Decitabine
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

Recurrent Leukemia, Refractory Leukemia Trial in Houston (Decitabine, Tegavivint)

Recruiting
  • Recurrent Leukemia
  • Refractory Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

MDS, MDS/MPN Crossover Syndromes Trial in Cleveland (5-azacytidine, Decitabine)

Recruiting
  • Myelodysplastic Syndromes
  • MDS/MPN Crossover Syndromes
  • Cleveland, Ohio
    Cleveland Medical Center, University Hospitals Seidman Cancer Ce
Aug 10, 2022

Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Boston, Massachusetts
  • +1 more
Mar 31, 2023

Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,

Completed
  • Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
  • +4 more
  • Decitabine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Acute Myelogenous Leukemia Trial in Rochester (Decitabine)

Completed
  • Acute Myelogenous Leukemia
  • Decitabine
  • Rochester, New York
    University of Rochester
Jul 1, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Decitabine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

Myeloid Malignancy, MDS, Myelofibrosis Trial in Boston (Navitoclax, Venetoclax, Decitabine)

Recruiting
  • Myeloid Malignancy
  • +4 more
  • Boston, Massachusetts
  • +2 more
Jul 21, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (STAT

Active, not recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • STAT Inhibitor OPB-111077
  • +3 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Dec 20, 2022

Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, MDS Trial in Minneapolis, Saint Louis, Rochester (Decitabine,

Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine
  • +2 more
  • Minneapolis, Minnesota
  • +2 more
Nov 2, 2022

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Decitabine
  • +3 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 22, 2023

Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Baltimore, Maryland
    University of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022

Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)

Recruiting
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 23, 2022